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Summary
Background Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for 
risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. 
We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with 
late-life brain structure, pathology, and cognition.
Methods Participants were from Insight 46, a neuroscience substudy of the ongoing longitudinal Medical Research 
Council National Survey of Health and Development, a birth cohort that initially comprised 5362 individuals born 
throughout mainland Britain in one week in 1946. Participants aged 69–71 years received T1 and FLAIR volumetric 
MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University College London (London, UK); all 
participants were dementia-free. Blood pressure measurements had been collected at ages 36, 43, 53, 60–64, and 
69 years. We also calculated blood pressure change variables between ages. Primary outcome measures were white 
matter hyperintensity volume (WMHV) quantified from multimodal MRI using an automated method, amyloid-β 
positivity or negativity using a standardised uptake value ratio approach, whole-brain and hippocampal volumes 
quantified from 3D-T1 MRI, and a composite cognitive score—the Preclinical Alzheimer Cognitive Composite 
(PACC). We investigated associations between blood pressure and blood pressure changes at and between 36, 43, 
53, 60–64, and 69 years of age with WMHV using generalised linear models with a gamma distribution and log link 
function, amyloid-β status using logistic regression, whole-brain volume and hippocampal volumes using linear 
regression, and PACC score using linear regression, with adjustment for potential confounders.
Findings Between May 28, 2015, and Jan 10, 2018, 502 individuals were assessed as part of Insight 46. 
465 participants (238 [51%] men; mean age 70·7 years [SD 0·7]; 83 [18%] amyloid-β-positive) were included in 
imaging analyses. Higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) at age 53 years and 
greater increases in SBP and DBP between 43 and 53 years were positively associated with WMHV at 69–71 years of 
age (increase in mean WMHV per 10 mm Hg greater SBP 7%, 95% CI 1–14, p=0·024; increase in mean WMHV per 
10 mm Hg greater DBP 15%, 4–27, p=0·0057; increase in mean WMHV per one SD change in SBP 15%, 3–29, 
p=0·012; increase in mean WMHV per 1 SD change in DBP 15%, 3–30, p=0·017). Higher DBP at 43 years of age 
was associated with smaller whole-brain volume at 69–71 years of age (–6·9 mL per 10 mm Hg greater DBP, 
–11·9 to –1·9, p=0·0068), as were greater increases in DBP between 36 and 43 years of age (–6·5 mL per 1 SD 
change, –11·1 to –1·9, p=0·0054). Greater increases in SBP between 36 and 43 years of age were associated with 
smaller hippocampal volumes at 69–71 years of age (–0·03 mL per 1 SD change, –0·06 to –0·001, p=0·043). Neither 
absolute blood pressure nor change in blood pressure predicted amyloid-β status or PACC score at 69–71 years 
of age.
Interpretation High and increasing blood pressure from early adulthood into midlife seems to be associated with 
increased WMHV and smaller brain volumes at 69–71 years of age. We found no evidence that blood pressure affected 
cognition or cerebral amyloid-β load at this age. Blood pressure monitoring and interventions might need to start 
around 40 years of age to maximise late-life brain health.
Funding Alzheimer’s Research UK, Medical Research Council, Dementias Platform UK, Wellcome Trust, Brain 
Research UK, Wolfson Foundation, Weston Brain Institute, Avid Radiopharmaceuticals.
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Introduction
Dementia affects 44 million people worldwide, a number 
predicted to triple by 2050.1 Up to a third of dementia risk 
might be modifiable, and a 5-year delay in onset could 
halve prevalence and associated costs.2 Hype rten sion is a 
well-established risk for vascular cognitive impairment 
mediated through cerebrovascular disease and has also 
been linked with Alzheimer’s disease.3 Hypertension in 
midlife confers the greatest risk for cognitive impairment.4,5 
However, midlife spans a period of more than 20 years 
(age 40–65 years), and it is unknown whether a sensitive 
period exists in which elevated or changing blood pressure 
is particularly damaging; and if so, which pathological 
mechanisms are involved.
We sought to determine the association between blood 
pressure and longitudinal blood pressure changes across 
a period of about 33 years, spanning early adulthood 
(36 years), midlife (43–64 years), and early late life 
(69 years), and cerebral small vessel disease, brain vol-
umes, and amyloid pathology in early late life. We hypoth-
esised that blood pressure would be differentially related 
to markers of different brain pathologies, and that blood 
pressure and changes in blood pressure in specific periods 
would affect brain pathology.
Methods
Study design and participants
Participants were from Insight 46, a substudy of the 
Medical Research Council (MRC) National Survey of 
Health and Development (NSHD), a birth cohort that 
initially comprised 5362 individuals born throughout 
main land Britain in 1 week in 1946,6 with follow-up 
including more than 20 contacts since birth. Eligibility 
criteria for Insight 46 have been described elsewhere 
Research in context
Evidence before this study
Hypertension, particularly in midlife, is associated with late-life 
dementia risk and with risk of clinically diagnosed Alzheimer’s 
disease. We reviewed previous work on blood pressure and brain 
health with a focus on white matter hyperintensities, brain 
volumes, and amyloid pathology. We searched PubMed for all 
articles published from database inception to Sept 31, 2018, 
with no language restrictions, for the keywords “blood 
pressure”, “hypertension”, “brain volume”, “hippocampal 
volume”, “atrophy”, “white matter hyperintensity”, “cerebral 
small vessel disease”, “amyloid”, “MRI”, “PET”, and “midlife”. 
Extensive published literature describes the positive association 
between hypertension and cerebral small vessel disease. 
Hypertension has also been associated with smaller brain 
volumes, with more consistent associations seen with midlife, 
rather than late life, measures of blood pressure. The association 
between blood pressure and amyloid burden is less clear. Several 
small studies found positive cross-sectional associations 
between higher blood pressure and elevated amyloid burden, 
whereas two large cohort studies, the Atherosclerosis Risk in 
Communities and the Mayo Clinic Study of Aging, did not 
observe an association between midlife hypertension and 
late-life amyloid burden. Midlife is generally defined as spanning 
a period between 40 years of age and 65 years of age. Studies to 
date have primarily investigated associations using a single 
measure in midlife, with the wide age range at measurement 
reducing the ability of these studies to determine whether there 
are specific periods in life when blood pressure, or change in 
blood pressure, particularly affect late-life brain health. 
Furthermore, some studies have used retrospective, clinically 
collected information on hypertension diagnosis, rather than 
prospectively collected blood pressure measurements from a 
community-based sample.
Added value of this study
Our study presents the first work, to our knowledge, examining 
the association between blood pressure taken prospectively at 
multiple timepoints, blood pressure changes, and brain 
pathologies and volumes measured systematically in a birth 
cohort in which all participants are of a near-identical age. 
The study design provides a unique opportunity to examine 
blood pressure changes in well-defined periods from early 
adulthood into midlife to late life and to explore their effect on 
brain pathologies and brain volumes. The use of data from this 
cohort, whose participants were assessed at the last visit over a 
2-year period, enables examination of associations without the 
confounding effect of age, which is strongly associated with all 
these measures. We find that early midlife, perhaps extending 
back into early adulthood, is a particularly sensitive period when 
elevated blood pressure and rapid blood pressure increases are 
associated with the development of subsequent white matter 
hyperintensities and smaller brain volumes. We did not observe 
an association between blood pressure or blood pressure change 
and late-life amyloid burden, providing additional evidence that 
associations observed between midlife hypertension and 
late-life dementia risk are unlikely to be mediated through 
amyloidogenic pathways. At the age of 69–71 years, in this 
cognitively normal cohort, associations between life course 
measures of blood pressure and cognition were not detected.
Implications of all the available evidence
Our results build upon existing evidence regarding the role of 
blood pressure in the development of subsequent brain 
pathology. However, although raised blood pressure might be 
associated with dementia and clinically diagnosed Alzheimer’s 
disease, it does not appear to affect risk for Alzheimer’s disease 
through amyloidogenic pathways at 69–71 years of age. Based 
on our results, the fourth to sixth decades of life might be a 
sensitive period when changes in blood pressure are particularly 
damaging to the brain. Findings suggest that routine and serial 
blood pressure measurement might need to start earlier than is 
typically considered (eg, around 40 years of age), and decisions 
to start treatment might need to be based not only on absolute 
blood pressure, but also longitudinal blood pressure change.
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(appendix p 1).7 Participants were assessed at University 
College London. Assessments included clinical and cog-
nitive assessment and combined PET-MRI.7 A comparison 
of health and demographic characteristics between par-
ticipants in Insight 46 and the larger MRC NSHD has 
previously been reported.8
Ethical approvals for the wider NSHD have been 
described.9 Insight 46 was approved by the Queen Square 
Research Ethics Committee. All participants provided 
written informed consent.
Procedures
Imaging was done using a single Biograph mMR 3T 
PET-MRI scanner (Siemens Healthcare, Erlangen), with 
simultaneous acquisition of dynamic PET-MRI data, 
including volumetric (1·1 mm isotropic) T1-weighted 
and T2-weighted Fluid Attenuated Inversion Recovery 
(FLAIR) sequences. The full imaging protocol has been 
described previously.7 PET data were acquired continu-
ously in list mode, during and following injection of 
370 MBq ¹⁸F florbetapir (Avid Radiopharmaceuticals, 
Philadelphia, PA). Amyloid burden was assessed over a 
10-min period, around 50 min after injection. Global 
stand ardised uptake value ratio was calculated from corti-
cal regions of interest, normalised to eroded subcortical 
white matter (appendix p 1). Positive or negative amyloid 
status was determined using a Gaussian mixture model 
applied to standardised uptake value ratio values, taking 
the 99th percentile of the lower Gaussian as the cutoff 
(0·6104).
Volumetric T1-weighted and FLAIR images underwent 
visual quality control before processing using auto-
mated pipelines:7 whole-brain volume segmentation using 
Multi-Atlas Propagation and Segmentation,10 hippocampal 
volume using Similarity and Truth Estimation for Propa-
gated Segmentations,11 with appropriate manual editing, 
and total intracranial volume using Statistical Parametric 
Mapping 12.12 A validated, unsupervised, automated algo-
rithm, Bayesian Model Selection (BaMoS),13 was used to 
segment white matter hyperintensities jointly from 3D T1 
and FLAIR images, followed by visual quality con trol, 
generating a global white matter hyperintensity volume 
(WMHV) including subcortical grey matter but excluding 
infratentorial regions. Further detail on BaMoS is provided 
in the appendix.
Neuropsychology included tests of episodic memory 
(Wechsler memory scale-revised logical memory test,14 
Face-Name Associative Memory Exam 1215), processing 
speed (Wechsler adult intelligence scale-revised digit 
symbol substitution test16) and global cognition (Mini-
Mental State Examination17), from which the Preclinical 
Alzheimer Cognitive Composite (PACC) was derived 
(appendix p 1).
Seated blood pressure was measured in the upper arm 
twice after 5 min of rest at ages 36, 43, 53, 60–64, and 
69 years. At ages 36 and 43 years, a Hawksley Random 
Zero sphygmomanometer was used and, at ages 53, 60–64, 
and 69 years, an Omron HEM-705 automated digital 
oscillometric sphygmomanometer was used. To ensure 
compatibility, published conversion equations were used.18 
The second blood pressure measure was used for analyses, 
unless missing. Hypertension was defined for descriptive 
purposes as blood pressure of 140/90 mm Hg or higher 
or self-reported clinical diagnosis. Pre script ion medica-
tion use was self-reported. At each time point, individuals 
were cate gorised according to use of antihypertensive 
medication.
Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) change for the periods between 36 and 43, 
43 and 53, 53 and 60–64, and 60–64 and 69 years of age, 
conditional on earlier measurements, was calculated as 
the residual from the regression of each blood pressure 
measure (from 43 years of age) on the earlier measures for 
each sex, using individuals with available data at all 
time-points. Residuals represent changes in blood pressure 
that differed from changes expected on average given 
the earlier blood pressure. Residuals were standardised, 
allowing com parison between periods.19
Vascular risk factors used in fully adjusted models 
included smoking status, hypercholesterolaemia, diabetes, 
and body-mass index (BMI) at time of scanning (appendix 
p 1). Genotyping of the two single nucleotide polymorph-
isms, rs439358 and rs7412, deter mined APOE genotype. 
Individuals were categorised as APOE ε4 carriers or non-
carriers. Adult socioeconomic position was defined as 
non-manual or manual on the basis of occupation at 
53 years of age according to the UK Registrar General’s 
Classification of Occupations. A childhood cognition 
score was calculated as described previously.20
Statistical analysis
Analyses were done in Stata version 14.1. Participants 
were included if they were dementia-free based on expert 
consensus, informed by clinical history, informant history, 
and Mini-Mental State Examination score (≥26). For 
imaging analyses, participants also needed acceptable 
quality amyloid PET-MRI. For WMHV and brain volume 
analyses, individuals with white matter pathologies not 
considered to be of vascular origin (eg, demyelination) 
or cortical infarcts inappropriately segmented were exclu-
ded. For brain volume analysis, individuals also needed a 
useable amyloid scan. Otherwise, all participants with 
available blood pressure measures at any time-point were 
included in the analysis.
Blood pressure at each visit was compared between those 
in Insight 46 and the whole cohort, using an unadjusted 
linear mixed effect model for men and women separately, 
using all available blood pressure measure ments. An 
unstructured residual variance-covariance matrix was used 
to model correlation between repeated measures in an 
individual.
Owing to the skewed distribution of WMHV, generalised 
linear models using the gamma distribution with log 
link were used to investigate associations between blood 
See Online for appendix
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pressure at each age separately and WMHV at 69–71 years 
of age. The association between blood pressure and severe 
WMHV (top quintile of WMHV) was also investigated 
using logistic regression. Linear regression was used to 
investigate associations between blood pressure and 
whole-brain volume and mean hippocampal volumes at 
69–71 years of age. Model 1 was adjusted for sex, total 
intracranial volume, and age-at-scan. Model 2 was also 
adjusted for antihypertensive medica tion use at time 
of blood pressure measurement. Model 3 additionally 
adjusted for blood pressure at 69 years of age to explore 
associations independently of current blood pressure. 
Model 4 additionally adjusted for poten tial cardiovascular 
confounders: smoking status, BMI, diabetic status, hyper-
cholesterolaemia status, childhood cognition, and adult 
socioeconomic position. For brain volume analyses, to 
explore blood pressure influences independently of meas-
urable brain pathologies, model 4 also adjusted for global 
WMHV and amyloid status.
Blood pressure change variables were then treated as 
the main predictor within generalised linear models or 
linear regression models. In model 1(c), all SBP or DBP 
conditional change variables were included and adjusted 
for sex, total intracranial volume and age-at-scan. In 
model 2(c), each conditional change variable was assessed 
individually and adjusted for change in antihypertensive 
medication status between timepoints under investigation 
and for other covariates described for model 4.
We used logistic regression to test associations between 
blood pressure at 36–69 years of age and amyloid status at 
age 69–71 years of age. Model 1 adjusted for sex. Model 2 
further adjusted for APOE ε4 status. Model 3 additionally 
adjusted for antihypertensive medication use. Model 4 
also adjusted for blood pressure (at 69 years of age). Addi-
tional vascular risk factors were not included in models 
due to the limited number of amyloid-positive individuals. 
Associations between blood pressure change and amyloid 
status were investigated using three models. Model 1(c) 
included all conditional change variables (SBP or DBP) 
within the same model, adjusting for sex. Model 2(c) addi-
tionally adjusted for APOE ε4 status. Model 3(c) assessed 
each trajectory separately and adjusted for change in 
antihypertensive medication status. A differ en tial influ-
ence of blood pressure (or change) on amyloid status by 
APOE ε4 status was tested using an interaction term in 
fully adjusted models.
An exploratory analysis investigated associations 
between blood pressure and blood pressure change and 
cogni tion at 69–71 years of age, using the PACC. The linear 
regress ion models that we used are described in the 
appendix (p 2).
Model assumptions were checked with regression diag-
nostics, including checks of linearity by examination of 
residuals. Possible non-linear associations were explored 
by introducing a quadratic term to fully adjusted models. 
Any suggestion of a non-linear association (p<0·05) 
was in vesti gated using linear spline modelling, with 
Participants assessed Overall value
Men Women Overall
Age at assessment 255 244 499 70·7 (0·7)
Age at scanning 238 227 465 70·7 (0·7)
Amyloid positive 232 225 457 83 (18%)
Whole brain volume, mL 227 218 445 1099·0 (98·4)
Hippocampal volume, mL 227 218 445 3·1 (0·3)
White matter hyperintensity volume, mL 233 220 453 3·1 (1·6–6·8)
Total intracranial volume, mL 233 220 453 1434·0 (132·3)
Mini-mental state examination score, out of 30 255 244 499 29·3 (0·9)
Preclinical Alzheimer Cognitive Composite z score 255 244 499 0·018 (0·66)
Standardised childhood cognition score 255 244 499 0·45 (0·64)
Systolic blood pressure, mm Hg
At 36 years of age 233 224 457 120·2 (13·7)
At 43 years of age 243 232 475 123·5 (13·7)
At 53 years of age 247 238 485 133·5 (19·0)
At 60–64 years of age 255 243 498 134·9 (16·9)
At 69 years of age 253 239 492 132·3 (16·1)
Diastolic blood pressure, mm Hg
At 36 years of age 233 224 457 78·4 (9·5)
At 43 years of age 243 232 475 80·4 (9·3)
At 53 years of age 247 238 485 83·1 (11·8)
At 60–64 years of age 255 243 498 77·0 (9·4)
At 69 years of age 253 239 492 73·4 (10·1)
Hypertensive*
At 36 years of age 231 224 455 71 (16%)
At 43 years of age 243 232 475 104 (22%)
At 53 years of age 247 241 488 226 (46%)
At 60–64 years of age 255 244 499 259 (52%)
At 69 years of age 253 241 494 274 (55%)
Antihypertensive medication use
At 36 years of age 234 226 460 7 (2%)
At 43 years of age 247 235 482 9 (2%)
At 53 years of age 248 242 490 57 (12%)
At 60–64 years of age 255 244 499 141 (28%)
At 69 years of age 251 235 486 194 (40%)
Smoking status at 68 years of age 255 244 499 ··
Current smoker ·· ·· 18 18 (4%)
Ex-smoker ·· ·· 311 311 (62%)
Never smoked ·· ·· 170 170 (34%)
Hypercholesterolaemia at 70 years of age† 255 244 499 398 (80%)
Diabetes at 70 years of age‡ 254 240 494 55 (11%)
Body-mass index at 70 years of age, kg/m² 255 244 499 27·7 (4·5)
Adult socioeconomic position§ 255 244 499 ··
Non-manual (Class I–IIIN) ·· ·· 424 424 (85%)
Manual (Class IIIM–V) ·· ·· 75 75 (15%)
APOE ε4 carrier (1 or 2 alleles) 253 244 497 146 (29%)
Values are n, mean (SD), n (%), or median (IQR). *Defined as blood pressure of 140/90 mm Hg or higher or self-reported 
clinical diagnosis. †Determined on the basis of self-reported use of cholesterol-lowering medication at 70 years of age or 
random total cholesterol 5 mmol/L or more at 69 years of age. ‡Determined on the basis of self-reported diabetic 
medication use at 70 years of age or HbA1c more than 6·5% or a self-reported diagnosis at 69 years of age. §Based on 
occupation at 53 years of age according to the UK Registrar General’s Classification of Occupations.
Table 1: Characteristics of dementia-free participants with at least one outcome of interest
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intro duction of knot points, using standard cutoffs for 
(pre-)hypertension and hypoten sion, where appropriate. 
Statistical significance was set at p<0·05.
Role of the funding source
The funders of the study had no role in study design, data 
collection, analysis, or interpretation, or report writing. 
All authors had full access to all the data in the study. 
The corresponding author had final responsibility for the 
decision to submit for publication.
Results
Between May 28, 2015, and Jan 10, 2018, 502 participants 
were assessed as part of Insight 46 at University College 
London (appendix p 3). Of the individuals assessed, 
471 (94%) completed the imaging protocol, of whom 
468 (93%) were dementia-free. Age at Insight 46 assess-
ment was similar in all individuals (mean 70·7 years 
[SD 0·7]). 83 (18%) were amyloid positive. Following 
imaging processing and quality control, data from 
457 (91%) were available for amyloid analysis, 445 (89%) 
for brain volume analysis, and 453 (90%) for WMHV 
analysis. 499 dementia-free individuals were included in 
the cognitive analysis. Participant characteristics are sum-
mar ised in table 1. Compared with those not completing 
the imaging protocol  (n=31), participants with full imaging 
and blood pressure data available (n=398) had marginally 
lower blood pressure at 69 years of age (132·1/73·3 mm Hg 
vs 133·6/74·2 mm Hg), lower BMI (27·6 mm Hg 
vs 30·4 kg/m²), and lower prevalence of current smoking 
(3% vs 7%), diabetes (10% vs 17%), and hyper chol estero-
laemia (79% vs 87%; appendix p 4). Women in Insight 46 
on average had SBP 1·8 mm Hg and DBP 0·9 mm Hg 
lower than those in the larger MRC NSHD cohort. Men 
in Insight 46 on average had SBP 2·1 mm Hg and 
DBP 0·6 mm Hg lower than those in the larger MRC 
NSHD cohort (appendix p 5).
Greater SBP and DBP at all timepoints was associated 
with greater WMHV, but this association only reached 
significance at 53 years of age (table 2; appendix p 7). In 
the fully adjusted model (model 4), a 10 mm Hg greater 
SBP at 53 years of age was associated with a relative 
increase in mean WMHV of 7% (relative increase 1·07, 
95% CI 1·01–1·14, p=0·024 ), and a 10 mm Hg greater 
DBP was associated with a 15% increase in mean WMHV 
(1·15, 1·04–1·27, p=0·0057). A similar association was 
seen between blood pressure at 53 years of age and severe 
WMHV (appendix p8). Introduction of a quadratic 
term suggested a non-linear associ ation between DBP at 
36 years of age and WMHV (quadratic p=0·015). A spline 
model with knot points at 60 mm Hg and 90 mm Hg 
found no association at blood pressures less than 
90 mm Hg but a significant positive association at blood 
pressures more than 90 mm Hg (exponentiated coeffi-
cient 2·07, 95% CI 1·13–3·79, p=0·018; appendix p 13). No 
non-linear associations were observed at other timepoints. 
Greater increases in SBP and DBP between timepoints 
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seemed to be associated with increased WMHV, with a 
significant association at 43–53 years of age (appendix pp 
6–7), with no evidence of non-linear associations (p>0·17, 
all tests). A 1 SD greater increase in SBP at 43–53 years of 
age was associated with 15% larger WMHV (1·15, 95% CI 
1·03–1·29, p=0·012), and one SD greater increase in DBP 
was associated with 15% larger WMHV (1·15, 1·03–1·20, 
p=0·017; appendix p 6).
There was no evidence that blood pressure at any 
age was associated with amyloid status (table 3). Blood 
pressure changes were not associated with amyloid status 
(appendix p 9). APOE ε4 status did not affect associations 
between blood pressure or blood pressure change and 
amyloid status (interaction p values all >0·13). There was 
no evidence of non-linear associations (p>0·13, all tests).
There was some evidence to suggest that higher SBP 
across timepoints might be associated with smaller 
whole-brain volume, with significant effects at 43 years of 
age (model 3, p=0·041) and 53 years of age (model 3, 
p=0·011; table 4). Although associations were attenuated 
in fully adjusted models, they remained significant at 
53 years of age (model 4, p=0·039; table 4). DBP at 
43 years of age had a negative effect on whole-brain 
volume, including in the fully adjusted model (model 4, 
p=0·0068; table 4; appendix pp 12); a 10 mm Hg higher 
DBP at that age was associated with a 6·9 mL reduction 
(95% CI –11·9 to –1·9) in whole-brain volume. Higher 
SBP at 43 years of age had a similar association with 
smaller mean hippocampal volume across models 
(model 4, p=0·048; table 5). In the fully adjusted model, a 
10 mm Hg higher SBP was associated with a 0·021 mL 
(95% CI –0·043 to –0·0002) smaller hippocampal 
volume. We found no associations between DBP and 
hippocampal volume (table 5).
At 53 years of age, there was evidence of a non-linear 
association between SBP and whole-brain volume (quad-
ratic p=0·011) and between SBP and hippocampal volume 
(quadratic p=0·044). Using knot points at 120 mm Hg and 
140 mm Hg and a fully adjusted model, no association 
existed below 140 mm Hg, but a negative association did 
exist between greater SBP and whole-brain volume at 
blood pressures greater than 140 mm Hg (β coefficient –9·0, 
95% CI –14·3 to –3·8, p=0·0008; appendix pp 12–13), 
suggesting that 140 mm Hg is a crucial threshold above 
which SBP at 53 years of age adversely affects whole-brain 
volume in late life. A similar non-linear pattern was 
observed for hippocampal volume (SBP >140 mm Hg 
β-coefficient –0·05, 95% CI –0·08 to –0·01, p=0·0063). 
Introduction of an additional knot point at 130 mm Hg did 
not alter findings (appendix p 13).
Greater increases in SBP between 36 and 43 years of 
age showed evidence of a borderline linear association, 
and greater increases between 43 and 53 years of age 
showed a significant linear association with smaller 
whole-brain volume. These associations were attenuated 
in the fully adjusted model (appendix p 10). Further 
analysis found that there were non-linear associations 
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between SBP change variables at 36–43 years of age 
(quadratic p=0·034) and 43–53 years of age (quadratic 
p=0·0074). Linear spline modelling with knot point at 
the average expected change (residual=0) showed that, 
among individuals with greater than expected change 
(residual >0), a greater SBP increase between 36 and 
43 years of age (β-coefficient –10·6, –18·6 to –2·7, 
p=0·0091) and 43 and 53 years of age (β-coefficient –12·0, 
–20·0 to –4·0, p=0·0033) was associated with smaller 
whole-brain volume. There was no evidence of an 
association in individuals with less than expected change 
in SBP (residual <0) at 36–43 years of age (p=0·18) or 
43–53 years of age (p=0·11; appendix p 13). There was a 
negative linear association between DBP changes at 
36–43 years of age and whole-brain volume, whereby a 
one SD greater increase in DBP at 36–43 years of age was 
associated with a 6·5 mL (95% CI –11·1 to –1·9) reduction in 
whole-brain volume (model 2, p=0·0054; appendix p 10).
Greater increases in SBP between 36 and 43 years of age 
were associated with smaller hippocampal volume. A one 
SD greater increase in SBP between 36 and 43 years 
was associated with 0·03 mL (95% CI –0·06 to –0·001) 
smaller hippocampal volume (model 2, p=0·043; appendix 
pp 11–12). There was no evidence of non-linear associations 
(p>0·13 all tests). DBP changes were not associated with 
hippocampal volume. All associations with hippo campal 
volume were substan tially attenuated when whole-brain 
volume was accounted for (data not shown).
No consistent associations were found between SBP or 
DBP at any age or blood pressure change and perform-
ance on the PACC (appendix pp 14–15).
Observing that the greatest mean increase in SBP was at 
43–53 years of age, and the greatest rate of decline in DBP 
was between 53 and 60–64 years of age (appendix p 5), 
we included SBP change at 43–53 years of age and DBP 
change between 53 and 60–64 years of age in a fully 
adjusted model, introducing an interaction term between 
the two change variables. This analysis suggested that 
there could be a greater effect of declining DBP on 
WMHV burden at 69–71 years of age in those who prev-
iously had a greater SBP increase (interaction p=0·038; 
appendix p 17–18). This interaction was not observed in 
amyloid (interaction p=0·83), brain volume (whole-brain 
volume interaction p=0·42; hippocampal volume inter-
action p=0·32), or cognitive (interaction p=0·32) models. 
To explore whether this finding might be driven by changes 
in arterial stiffness, we examined the associ ation between 
pulse pressure change variables and WMHV. None of 
these associations were significant (data not shown).
In fully adjusted models including adjustment for total 
intracranial volume, men had less WMHV (p=0·0063) 
and smaller whole-brain volume (p=0·0032) than women. 
Diabetics had smaller whole-brain volume (p=0·0074; 
appendix p 16). APOE ε4 carriers were more likely to be 
amyloid positive (p<0·0001; appendix p 16). Male sex 
(p<0·0001) and lower socioeconomic position (p=0·0009) 
predicted worse cognition (appendix p 16). Child hood 
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cognition was positively associated with the PACC 
(p<0·0001; appendix p 16). No con sistent associations 
existed between antihypertensive medication use and 
outcome measures (appendix p 16).
Discussion
In this cohort of dementia-free individuals of virtually 
identical age recruited from across mainland Britain, we 
show that, even accounting for blood pressure in late life, 
higher blood pressure in midlife seems to be associated 
with greater cerebral small vessel disease burden and 
smaller whole-brain and hippocampal volumes at around 
70 years of age. We show associations between more 
rapid blood pressure increases in early midlife, and 
smaller brain volumes and greater WMHV in late life. 
We found no evidence that blood pressure or blood 
pressure changes affect amyloid status.
Our observations are in agreement with previous work 
showing a particularly strong association between mid life 
blood pressure and late-life cerebral small vessel disease.21 
Both SBP and DBP at 53 years of age were associated with 
late-life cerebral small vessel disease, although the effect 
size was almost double for DBP than for SBP. We found 
some evidence of a non-linear association between DBP 
in early adulthood, at 36 years of age, and late-life WMHV, 
with DBP increases greater than 90 mm Hg associated 
with greater WMHV. How ever, we did not find non-linear 
associations at other timepoints, so this finding needs 
further confirmation.
Although several cross-sectional studies have reported 
an association between higher blood pressure and 
amyloid burden,22,23 our negative finding is consistent 
with those from two large cohort studies that specifically 
examined midlife hypertension.24,25 Our work extends 
these previous findings by using continuous measures of 
blood pressure, exploring the associations with SBP and 
DBP separately using prospectively acquired measures at 
multiple time-points, as well as specifically investigating 
blood pressure changes over time. We also found no 
evidence of interaction between APOE ε4 carrier status, 
blood pressure, or blood pressure changes and amyloid 
status at 69–71 years of age. Taken together, these data 
pro vide further evidence that, if hypertension increases 
Alzheimer’s disease risk, this increase occurs through 
non-amyloidogenic pathways, at least in those affected by 
their early 80s.
Greater DBP at 43 years of age and SBP at 53 years 
of age were most associated with smaller whole-brain 
volume, independently of contemporaneous blood pres-
sure. There was a non-linear association with SBP at 
53 years of age, whereby measures higher than 140 mm 
Hg were particularly detrimental to late-life whole-brain 
volume, suggesting a threshold effect for SBP. Simi-
larly, greater increases in DBP at 36–43 years of age and 
greater increases in SBP at 36–53 years of age (ie, from 
early adulthood into midlife) were both associ ated with 
smaller whole-brain volume, independent of white matter 
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hyper intensity load and amyloid burden. These findings 
are consistent with evidence from the Framingham Heart 
Study that vascular risk factors at younger ages were most 
strongly associated with lower brain volume in later life.26 
We did not observe dis proportionate hippocampal volume 
loss, as would be typical for Alzheimer’s disease, suggest-
ing that raised blood pressure mediates its damaging 
effects through global brain volume changes. Potential 
mechanisms by which raised blood pressure might 
influence brain volume include tau pathology27 or 
hypertension-related microstructural damage or infarc-
tion.28 Finally, we cannot exclude the possibility that blood 
pressure and brain volume share common predictors (eg, 
genetic factors). Previous work in the NSHD cohort has 
shown associations between rapid blood pressure rises at 
43–53 years of age and greater left cardiac ventricular 
mass at 60–64 years of age, suggesting that this period is 
sensitive for cardiac as well as cerebral health19 or that 
cardiac changes might be on the causal pathway to 
cerebral damage.
We did not observe an association between blood 
pressure and cognition, as reported in other cohorts.29–31 
We used a composite cognitive measure that might not 
have been cross-sectionally sensitive, particularly in a 
dementia-free cohort, noting that previous studies30,31 
have found associations between blood pressure and 
longi tudinal cognitive change. Although the PACC incor-
porates a measure of executive function shown to be the 
cognitive domain most strongly influenced by blood 
pressure,30 it was originally developed to be sensitive to 
cognitive changes in preclinical Alzheimer’s disease 
(before the development of overt cognitive symptoms); 
there fore, our findings are consistent with the absence of 
association between blood pressure and amyloid status.
Previous studies have produced conflicting findings 
regarding whether elevated SBP or DBP more strongly 
affects cerebral small vessel disease and brain volumes.32–34 
Differences might relate to the different populations 
studied, or timing of measurements, perhaps mediated 
by differential endothelial sensitivity to haemodynamic 
changes at different ages. As with other studies, we 
observed different patterns of change in SBP and DBP 
over time. DBP declines after 50–60 years of age, whereas 
SBP continues to increase.35 Hypotension might be more 
detrimental in late life to cerebral small vessel disease 
and brain volumes in cognitively normal individuals, 
particularly if prev iously hypertensive,21,36 perhaps due 
to shifts in the autoregula tory curve and cerebral hypo-
perfusion. We found some evidence for this finding, 
showing a greater effect of declining DBP on WMHV 
burden, but not brain volume, in individuals who had 
previously had a greater rise in SBP. Alternatively, this 
finding might be mediated by increas ing arterial 
stiffness, which is associated with declining DBP, 
although we did not find a direct association between 
pulse pressure, a proxy marker of arterial stiffness, and 
subsequent WMHV.
Our findings are particularly relevant considering the 
findings from the SPRINT MIND study,37 which showed 
that intensive blood pressure control reduced risk of mild 
cognitive impairment, but not dementia. This finding 
might be partly due to the early termination of the trial 
owing to clear cardiovascular benefits in the intensive 
treatment group. However, the older age of participants 
(2636 [28%] of 9361 aged ≥75 years) might also have 
contributed, and our data would suggest that, although 
vascular risk control is important at all ages, effects on 
blood pressure might be more pronounced if targeted at 
an earlier age.
This study has several strengths. Participants are broadly 
representative of the population of mainland Britain born 
in 1946 and were of similar age at assessment. All 
participants had serial prospective measurements of blood 
pressure, allowing dynamic changes in blood pressure 
across the life course to be studied. Limitations inherent 
in any birth cohort are secular effects. All indi viduals went 
through midlife at the same time and are likely to have 
been exposed to similar hypertension treatments and 
targets, which might differ from those of individuals born 
in other periods. Furthermore, although participants have 
similar blood pressure profiles to the main cohort, we 
have previously shown that individuals with lower socio-
economic position, lower cognition, and more health 
problems are under-represented in Insight 46, suggesting 
that we might underestimate effect sizes compared with 
the general population.8 Other limitations include the use 
of static rather than ambulatory blood pressure measure-
ments, which more closely correlate with end-organ 
damage.38 We treated amyloid burden as a binary variable, 
which is a common approach, but means that small blood 
pressure influences on amyloid burden might not be 
detected. We did not investigate associations with lacunes 
or subcortical infarcts, noting that these were present in a 
small proportion (36 [7%] of 471), or microbleeds, and we 
do not have measures of tau pathology. Insight 46 is a 
cohort consisting of exclusively white British participants, 
which might reduce generalisability to non-white popula-
tions, and their relatively young age (early 70s) might 
reduce generalisability to older populations who have 
larger pathological burden. This cohort is mostly cog-
nitively healthy, meaning that we can show associations 
between blood pressure and brain pathology, but not with 
cognitive impairment.
This work shows that the fourth to sixth decade, from 
early adulthood into midlife, might be a sensitive period 
when greater blood pressure affects brain pathologies in 
late life, and that greater increases in blood pressure and, 
in the case of DBP, decline thereafter might be particularly 
harmful. These findings suggest that routine serial blood 
pressure measurement might need to start around 
40 years of age (if not before), decisions to start treatment 
should account for longitudinal blood pressure change, 
and different approaches to blood pressure management 
might be needed at different ages. Associations between 
Articles
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blood pressure and increased risk for dementia are likely 
to be mediated through effects on cerebral small vessel 
disease and brain volumes and not amyloid accumulation.
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